摘要
目的探讨胸腺肽治疗重症肺炎合并脓毒血症的疗效。方法收集2013年12月~2015年10月期间我院收治的重症肺炎合并脓毒血症患者共82例,随机分为观察组和对照组,每组41例,对照组给予常规治疗;观察组在给予常规治疗的基础上皮下注射胸腺肽治疗,两组患者均连续治疗5d。比较两组临床疗效、机械通气时间及ICU住院时间、IL-6、TNF-α、CD4^+、CD8^+、CD4^+/CD8^+。结果观察组临床治疗显效率(95.12%)明显高于对照组(80.48%),机械通气时间及ICU住院时间均少于对照组,差异有统计学意义(P<0.05)。治疗后观察组和对照组IL-6、TNF-α、CD8^+水平与治疗前比较均出现明显降低,CD4^+、CD4^+/CD8^+与治疗前比较均出现明显升高,观察组IL-6、TNF-α、CD8^+水平低于对照组,CD4^+、CD4^+/CD8^+高于对照组,两组差异有统计学意义(P<0.05)。结论胸腺肽治疗重症肺炎合并脓毒血症临床疗效较好,可使患者的临床症状得到明显改善,免疫功能明显提高,可作为一种治疗重症肺炎合并脓毒血症有效的方法在临床推广应用。
Objective To investigate the therapeutic effect of severe pneumonia with sepsis treated with Thymosin. Methods 82 cases of severe pneumonia with sepsis were selected from December 2013 to October 2015 in our hospital,all the patients were randomly divided into the observation group and the control group（n=41）,the patients of the control group were given conventional treatment, the patients of the observation group were given thymosin infections on the basis of the Conventional treatment,the patients in two groups were continuous therapy five days.The clinical efficacy,Duration of mechanical ventilation,ICU stay time,IL-6,TNF-α,CD4~＋,CD8~＋,CD4~＋/CD8~＋of two groups were compared. Results The clinical efficiencyof the observation group（95.12%） was significantly higher than the control group（80.48%）,Duration of mechanical ventilation and ICU stay time were less than the control group,the difference was statistically significant（P 〈0.05）.After treatment,IL-6,TNF-α,CD8~＋levels of the observation group and the control group were lower than before treatment,CD4~＋,CD4~＋/CD8~＋were significant higher than before treatment,the observation group IL-6, TNF-α, CD8~＋ levels were lower than the control group,CD4~＋,CD4~＋/CD8~＋were higher than the control group, the difference was statistically significant（P 〈0.05）. Conclusion The therapeutic effect of Thymosin severe pneumonia sepsis better enable clinical symptoms significantly improved immune function improved significantly,as a treatment for severe pneumonia sepsis and effective method in clinical application.
出处
《中国医药科学》
2016年第3期82-84,共3页
China Medicine And Pharmacy
